<DOC>
	<DOCNO>NCT02759783</DOCNO>
	<brief_summary>Metastatic spread cancer primary site distant organ commonest cause death cancer . The term oligometastases describes intermediate metastatic state , cancer exists limit number metastasis first , cell acquire ability metastasise widely . For large majority solid cancer , metastatic disease diagnose chance cure small . There several situation case , know stereotactic body radiotherapy ( SBRT ) oligometastatic disease alter outcomes whether toxicity burden treatment justify . SBRT target radiotherapy destroys cancer cell area body aim however low dose radiation may receive surround tissue . It difficult quantify incidence patient multiple primary cancer develop interval representative oligometastatic stage IV disease , ( defined purpose trial ≤ 3 metastatic site ) . However increase use surveillance imaging , together improve diagnostic sensitivity lead diagnosis patient asymptomatic oligometastatic relapse become common clinical occurrence . The CORE study randomize control trial conduct patient cancer one three primary site oligometastatic disease relapse common clinical scenario : breast , prostate non-small cell lung cancer ( NSCLC ) . The study evaluate use SBRT patient population . Eligible patient consent participate clinical trial randomize receive standard care standard care plus SBRT hope recruit approximately 206 patient study primary outcome measure progression free survival .</brief_summary>
	<brief_title>Conventional Care Versus Radioablation ( Stereotactic Body Radiotherapy ) Extracranial Oligometastases</brief_title>
	<detailed_description>CORE phase II/III , multi-centre , non-blinded , parallel group randomise control trial patient breast , prostate NSCLC primary cancer compare standard care ( SOC ) without SBRT extra-cranial metastasis . The aim phase II study demonstrate 1 ) feasibility recruitment , 2 ) deliverability study multi-centre set 3 ) activity SBRT , base progression free survival , across three tumour type . If three aim achieve trial amend roll parallel tumour-site specific phase III trial . Eligible patient either primary breast , prostate NSCLC present ≤3 extra-cranial , metachronous , oligometastases , suitable SBRT . Patients randomise 1:1 ratio either SOC SOC addition SBRT . Choice SOC treatment discretion local oncologist define per patient prior randomisation ( see section 8 ) . Patients randomise SBRT+SOC receive dose fractionation regimen dependent metastatic site proximity dose limit organ normal tissue . Treatment take place within 6 week randomisation . The average scheme would 3 treatment 5 day maximum period SBRT duration could 8 treatment 19 day . All patient review every 3 month clinical examination tumour marker ( applicable ) year 1 2 , 6 monthly thereafter 5 year . Staging follow imaging protocol tumour type dependent : - Breast : 3 monthly CT scan year 1 2 , 6 monthly thereafter 5 year . - NSCLC : 3 monthly CT scan year 1 2 , 6 monthly year 3 , annually 5 year . - Prostate : CT scan perform 6 , 12 24 month image triggered appropriate PSA rise . A rise PSA define 2 successive PSA rise nadir , measure minimum 4 week apart . If overall PSA rise double time ≥ 3 month PSA level double original PSA value trial entry clinically indicate , restaging consider . All patient toxicity assessment clinic visit patient report quality life ( QOL ) assessment 3 , 6 , 12 , 18 24 month .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>1 . Age ≥ 18 year 2. WHO performance status 02 3 . Histological confirmation primary malignancy ( histological confirmation metastasis mandatory perform situation diagnostic uncertainty ) . Patients breast , nonsmall cell lung prostate primary malignancy eligible . 4 . Predicted life expectancy &gt; 6 month 5 . ≤ 3 metastatic lesion ( total ) . A maximum 2 different organ system ( e.g liver , lung , bone , nodal ) may contain metastasis total number lesion must exceed 3 . For example , patient 3 liver metastasis 1 liver metastasis 2 lung metastasis would eligible . A patient 1 lung metastasis , 1 liver metastasis adrenal metastasis ineligible . 6 . All metastasis must visible , image define target suitable treatment SBRT accordance dose fractionation option specify protocol . ( See associate CORE trial radiotherapy delivery guideline detail SBRT guidance metastatic site ) 7 . Patients receive prior ablative therapy ( e.g . surgery , RFA SBRT ) metastatic disease eligible , long site control imaging point trial entry total number metastasis time since diagnosis metastatic disease exceed 3 . Patients 2 3 metastasis ablative therapy ( e.g . surgery/RFA ) 1 site deem appropriate part standard therapy may enter trial ablative treatment , follow successful delivery clinical treatment . 8 . Metachronous metastatic disease presentation . Primary site must control . Diseasefree interval completion radical treatment ( include adjuvant therapy ) diagnosis metastasis : Breast : ≥ 6 month . Patients relapse whilst adjuvant endocrine therapy eligible . NSCLC : ≥ 4 month Prostate : ≥ 6 month . Patients relapse whilst adjuvant endocrine therapy eligible . 9 . Systemic therapy naïve metastatic setting . Prior systemic therapy permit minimum time interval ( per primary site ) last dose cytotoxic chemotherapy first fraction SBRT allow per primary site list criterion 4 . Concurrent endocrine therapy SBRT allow . 10 . Adequate baseline organ function allow SBRT relevant target ( please see relevant appendix dependent location metastatic subsite necessary baseline investigation ) . 11 . Negative pregnancy test ( woman childbearing potential ) 12 . Absence psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition discuss patient registration trial . 13 . Written inform consent Exclusion criterion 1 . Intracranial metastasis 2 . Malignant pleural effusion 3 . Malignant peritoneal disease 4 . Any single metastasis &gt; 6cm , ( &gt; 5cm lung metastasis ) 5 . Prior radiotherapy site precludes safe delivery SBRT . 6 . Comorbidities preclude stag follow imaging , preclude procedure require facilitate SBRT 7 . Locoregional nodal relapse surgery regional field radiotherapy standard care . Patients supraclavicular , axillary internal mammary nodal relapse breast cancer exclude . 8 . Spinal cord compression . 9 . Any condition significant clinical comorbidities preclude safe delivery SBRT ( eg history clinically significant diffuse interstitial lung disease SBRT lung metastasis lesion adjacent lung consider clinically significant colitis ie ulcerative colitis /Crohn 's disease SBRT pelvis abdomen consider ) . 10 . Prostate cancer patient previously relapse Androgen Deprivation Therapy ( ADT ) CAB receive abiraterone , enzalutamide docetaxel ineligible . 11 . Patients whose entry trial cause unacceptable clinical delay plan management .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Radiotherapy</keyword>
	<keyword>oligometastases</keyword>
	<keyword>SBRT</keyword>
</DOC>